A Safety Study of ABI-007 for In-Stent Restenosis
- Conditions
- Coronary Artery DiseaseAngina Pectoris
- Interventions
- First Posted Date
- 2004-10-07
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 76
- Registration Number
- NCT00093223
- Locations
- 🇺🇸
Abraxis BioScience, Inc., Durham, North Carolina, United States
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT00093145
- Locations
- 🇺🇸
Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States
🇺🇸Breastlink Med Group, Long Beach, California, United States
🇺🇸Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford, Connecticut, United States
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
- Conditions
- MelanomaMetastases
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT00093119
- Locations
- 🇺🇸
Abraxis BioScience Inc., Durham, North Carolina, United States
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- First Posted Date
- 2004-09-15
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 77
- Registration Number
- NCT00091624
- Locations
- 🇺🇸
Cleveland Clinic Myeloma Program, Cleveland, Ohio, United States
Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas
- Conditions
- GlioblastomaMalignant Gliomas
- First Posted Date
- 2003-12-19
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00074646
- Locations
- 🇺🇸
Neuro Oncology BranchNational Cancer Institute, Bethesda, Maryland, United States
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT00073723
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2006-12-19
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT00072722
- Locations
- 🇺🇸
University of Colorado Health Science Center, Denver, Colorado, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Other: Physician Choice
- First Posted Date
- 2003-11-05
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 358
- Registration Number
- NCT00071799
- Locations
- 🇪🇸
Hospital de Leon, Leon, Spain
🇵🇱Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland
🇦🇺The Royal Perth Hospital, Perth, Western Australia, Australia
A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)
- First Posted Date
- 2003-08-27
- Last Posted Date
- 2008-01-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00067743
- Locations
- 🇺🇸
Swedish Pain Management, Seattle, Washington, United States
🇺🇸UNC Hospitals University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2003-07-23
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 222
- Registration Number
- NCT00065351
- Locations
- 🇺🇸
Providence St. Joseph Medical Center/Cancer Center, Burbank, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States